Vertex Pharmaceuticals’ Promising Market Position and Opioid-Sparing Solution Drive Buy ...
Wells Fargo analyst Mohit Bansal has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. Mohit Bansal has given his ...
Vertex Pharmaceuticals’ Promising Developments and Strategic Market Positioning Reinforce ...
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Vertex Pharmaceuticals: A Long-Term Growth Monster
Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts ...
SNAP Down 35% Year to Date: How Should Investors Play the Stock?
Despite an expanding product offering, Snap suffers from sluggish brand-oriented revenues. Stiff competition is a headwind.
Vertex 10% Owner Trades Company's Stock
It was reported on October 15, that ITEM SECOND IRR TRUST FBO ANNE MARIE WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex VERX executed a significant insider sell, according to an ...